Resultats de la cerca - Peter D’Andrea

  • Mostrar 1 - 5 resultats de 5
Refinar resultats
  1. 1
    Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study

    Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study per Kai-Michael Beeh, Stephanie Korn, Jutta Beier, Dalal Jadayel, Michelle Henley, Peter D’Andrea, Donald Banerji

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients

    Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients per Jadwiga A. Wedzicha, Ronald Dahl, Roland Buhl, Agnes Annette Schubert-Tennigkeit, Hungta Chen, Peter D’Andrea, Robert Fogel, Donald Banerji

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease

    Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease per James F. Donohue, Paul Jones, Christian Bartels, Jessica Marvel, Peter D’Andrea, Donald Banerji, David G. Morris, Francesco Patalano, Robert Fogel

    Publicat 2017
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  4. 4
    A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study

    A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study per Kenneth R. Chapman, Kai Michael Beeh, Jutta Beier, Eric Bateman, Anthony D’Urzo, Robert Nutbrown, Michelle Henley, Hungta Chen, Tim Overend, Peter D’Andrea

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study

    Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma... per Huib A.M. Kerstjens, Jorge Máspero, Kenneth R. Chapman, Richard N. van Zyl-Smit, Motoi Hosoe, Ana-Maria Tanase, Catherine Lavecchia, Abhijit Pethe, Xu Shu, Peter D’Andrea

    Publicat 2020
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: